CureVac (CVAC)
(Delayed Data from NSDQ)
$3.23 USD
-0.06 (-1.82%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.25 +0.02 (0.62%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for CureVac NV falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 438 | 527 | 916 | 1,514 | -99,999 |
Receivables | 21 | 7 | 21 | 1 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 27 | 25 | 63 | 17 | NA |
Other Current Assets | 31 | 56 | 55 | 56 | NA |
Total Current Assets | 518 | 615 | 1,055 | 1,588 | NA |
Net Property & Equipment | 256 | 209 | 189 | 76 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 1 | 1 | 3 | 1 | NA |
Intangibles | 31 | 33 | 15 | 16 | NA |
Deposits & Other Assets | 2 | 2 | 2 | 7 | NA |
Total Assets | 853 | 907 | 1,300 | 1,726 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 52 | 77 | 143 | 25 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 5 | 5 | 4 | 4 | NA |
Accrued Expenses | 0 | 0 | 0 | 0 | NA |
Income Taxes Payable | 1 | 1 | 1 | 0 | NA |
Other Current Liabilities | 144 | 81 | 253 | 254 | NA |
Total Current Liabilities | 202 | 165 | 401 | 283 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 40 | 39 | 29 | 31 | NA |
Other Non-Current Liabilities | 52 | 141 | 97 | 600 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 294 | 345 | 527 | 914 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 29 | 25 | 25 | 25 | NA |
Capital Surplus | 2,225 | 1,915 | 1,940 | 1,525 | NA |
Retained Earnings | -1,695 | -1,376 | -1,186 | -737 | NA |
Other Equity | 0 | 0 | 0 | 0 | NA |
Treasury Stock | 0 | 2 | 7 | 0 | NA |
Total Shareholder's Equity | 559 | 562 | 773 | 813 | NA |
Total Liabilities & Shareholder's Equity | 853 | 907 | 1,300 | 1,726 | NA |
Total Common Equity | 559 | 562 | 773 | 813 | 0 |
Shares Outstanding | 223.80 | 194.90 | 187.10 | 181.10 | NA |
Book Value Per Share | 2.50 | 2.88 | 4.13 | 4.49 | 0.00 |
Fiscal Year End for CureVac NV falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 222 | 330 | 438 | 509 | 592 |
Receivables | 27 | 22 | 21 | 11 | 7 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 28 | 27 | 25 | 24 |
Other Current Assets | 21 | 30 | 31 | 39 | 34 |
Total Current Assets | 271 | 410 | 518 | 584 | 658 |
Net Property & Equipment | 256 | 259 | 256 | 249 | 239 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 1 | 1 | 1 | 1 | 1 |
Intangibles | 29 | 34 | 31 | 33 | 35 |
Deposits & Other Assets | 2 | 2 | 2 | 2 | 2 |
Total Assets | 600 | 750 | 853 | 917 | 981 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 8 | 20 | 52 | 14 | 15 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 5 | 6 | 5 | 6 | 6 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 1 | 1 | 1 | 1 | 1 |
Other Current Liabilities | 104 | 156 | 144 | 144 | 149 |
Total Current Liabilities | 118 | 182 | 202 | 164 | 170 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 37 | 39 | 40 | 40 | 38 |
Other Non-Current Liabilities | 39 | 52 | 58 | 64 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 194 | 264 | 294 | 262 | 273 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 29 | 29 | 29 | 29 | 29 |
Capital Surplus | 2,217 | 2,233 | 2,225 | 2,237 | 2,239 |
Retained Earnings | -1,841 | -1,777 | -1,695 | -1,610 | -1,560 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 405 | 485 | 559 | 656 | 708 |
Total Liabilities & Shareholder's Equity | 600 | 750 | 853 | 917 | 981 |
Total Common Equity | 405 | 485 | 559 | 656 | 708 |
Shares Outstanding | 223.80 | 223.80 | 223.80 | 223.80 | 223.80 |
Book Value Per Share | 1.81 | 2.17 | 2.50 | 2.93 | 3.16 |